Education
About Us
Working with TipRanks
Follow Us
Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
RESEARCH TOOLSreports
2509 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$5.95 - HK$30.95
Previous CloseN/A
Volume3.00K
Average Volume (3M)383.35K
Market Cap
N/A
Enterprise ValueHK$1.60B
Total Cash (Recent Filing)HK$556.55M
Total Debt (Recent Filing)HK$527.60M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 15, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding222,071,600
10 Day Avg. Volume618,000
30 Day Avg. Volume383,346
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$15.00Price Target Upside-29.97% Downside
Rating ConsensusHold
Number of Analyst Covering0
Qyuns Therapeutics Co., Ltd. Class H News
2509 FAQ
What was Qyuns Therapeutics Co., Ltd. Class H’s price range in the past 12 months?
Qyuns Therapeutics Co., Ltd. Class H lowest stock price was HK$5.95 and its highest was HK$30.95 in the past 12 months.
What is Qyuns Therapeutics Co., Ltd. Class H’s market cap?
Currently, no data Available
When is Qyuns Therapeutics Co., Ltd. Class H’s upcoming earnings report date?
Qyuns Therapeutics Co., Ltd. Class H’s upcoming earnings report date is Aug 15, 2025 which is in 7 days.
How were Qyuns Therapeutics Co., Ltd. Class H’s earnings last quarter?
Qyuns Therapeutics Co., Ltd. Class H released its earnings results on Mar 28, 2025. The company reported -HK$0.798 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.798.
Is Qyuns Therapeutics Co., Ltd. Class H overvalued?
According to Wall Street analysts Qyuns Therapeutics Co., Ltd. Class H’s price is currently Overvalued.
Does Qyuns Therapeutics Co., Ltd. Class H pay dividends?
Qyuns Therapeutics Co., Ltd. Class H does not currently pay dividends.
What is Qyuns Therapeutics Co., Ltd. Class H’s EPS estimate?
Qyuns Therapeutics Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qyuns Therapeutics Co., Ltd. Class H have?
Qyuns Therapeutics Co., Ltd. Class H has 222,071,600 shares outstanding.
What happened to Qyuns Therapeutics Co., Ltd. Class H’s price movement after its last earnings report?
Qyuns Therapeutics Co., Ltd. Class H reported an EPS of -HK$0.798 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.223%.
Which hedge fund is a major shareholder of Qyuns Therapeutics Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2509
Company Description
Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. Class H (2509) is a pharmaceutical company engaged in the development, manufacturing, and commercialization of innovative therapeutic products. The company operates in the biotech sector, focusing on producing cutting-edge drugs and treatments for various medical conditions. Its core offerings include a range of proprietary medications and therapeutic solutions aimed at improving patient outcomes and addressing unmet medical needs.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Clover Biopharmaceuticals Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―